InnoCare Pharma announces the inclusion of Obutinib in the CSCO Lymphoma Diagnosis and Treatment Guidelines as a Grade I recommendation for first-line treatment of CLL/SLL

InnoCare Pharma announces the inclusion of Obutinib in the CSCO Lymphoma Diagnosis and Treatment Guidelines as a Grade I recommendation for first-line treatment of CLL/SLL

InnoCare Pharma announces the inclusion of Obutinib in the CSCO Lymphoma Diagnosis and Treatment Guidelines as a Grade I recommendation for first-line treatment of CLL/SLL

User: DTnewswire dongtaibao888

Views: 0

Uploaded: 2025-04-30

Duration: 01:18